Clinical pharmacology and therapeutics, 2007-08, Vol.82 (2), p.210-214
2007
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Preclinical Predictors of Clinical Safety: Opportunities for Improvement
- Ist Teil von
- Clinical pharmacology and therapeutics, 2007-08, Vol.82 (2), p.210-214
- Ort / Verlag
- New York, NY: Nature Publishing
- Erscheinungsjahr
- 2007
- Quelle
- Wiley-Blackwell Journals
- Beschreibungen/Notizen
- Toxicology studies in animals are required by regulatory authorities worldwide to provide assurances that clinical testing of pharmaceutical candidates can be conducted safely.1 Safety concerns from animal studies account for over 20% of attritions from drug development.2 As discordance between humans and animals is expected, two goals of safe and efficient drug development must be (1) to improve the human relevance of animal testing with new models and technologies, and (2) to advance quickly to clinical testing armed with improved safety biomarker tools. Clinical Pharmacology & Therapeutics (2007) 82 210–214. doi:10.1038/sj.clpt.6100243; published online 16 May 2007
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0009-9236eISSN: 1532-6535DOI: 10.1038/sj.clpt.6100243Titel-ID: cdi_crossref_primary_10_1038_sj_clpt_6100243
- Format
- –
- Schlagworte
- Animals, Biological and medical sciences, Clinical Trials as Topic - methods, Disease Models, Animal, Drug Approval - legislation & jurisprudence, Drug Approval - methods, Drug Evaluation, Preclinical - methods, Drug Evaluation, Preclinical - standards, Drug-Related Side Effects and Adverse Reactions - chemically induced, Drug-Related Side Effects and Adverse Reactions - prevention & control, Drugs, Investigational - adverse effects, Drugs, Investigational - pharmacology, Drugs, Investigational - therapeutic use, Humans, Medical sciences, Pharmacology. Drug treatments